<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666627</url>
  </required_header>
  <id_info>
    <org_study_id>STH 14463</org_study_id>
    <nct_id>NCT00666627</nct_id>
  </id_info>
  <brief_title>Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects</brief_title>
  <official_title>A 2-year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine if the three licensed bisphosphonates (alendronate, ibandronate and&#xD;
      risedronate):a) affect the peripheral skeleton differently, as assessed by quantitative&#xD;
      ultrasound of bone (QUS), peripheral quantitative computed tomography (pQCT) and dual-energy&#xD;
      x-ray absorptiometry (DXA)? b) have different effects on bone cells and their activity as&#xD;
      assessed by flow cytometry and biochemical markers of bone cell activity? The aim of the&#xD;
      study is to compare the effects of three licensed bisphosphonates on bone quantity and&#xD;
      quality. There has been no such study before. Most of the measures of bone quantity and&#xD;
      quality used in this protocol have not been studied with any of these three agents. The&#xD;
      novelty of the study necessitates the establishment of reference ranges and this explains the&#xD;
      need for the inclusion of a group of young women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have been a number of randomised controlled trials examining the effect of&#xD;
      bisphosphonates on fracture risk. The results of these trials have not been uniform,&#xD;
      especially in relation to non-vertebral fractures. We have proposed that much of the fracture&#xD;
      risk reduction with risedronate can be explained by the reduction in bone resorption markers&#xD;
      (Eastell et al, 2003). Each of these three bisphosphonates reduces bone resorption markers,&#xD;
      and alendronate and ibandronate are at least as effective as risedronate in this regard.&#xD;
      However, there have been few direct comparisons of the different bisphosphonates on surrogate&#xD;
      endpoints such as bone mineral density and bone turnover markers. This raises the question of&#xD;
      whether the bisphosphonates might affect some other aspect of bone strength, such as 'bone&#xD;
      quality'.&#xD;
&#xD;
      The purpose the study is to determine whether three licensed bisphosphonates affect the&#xD;
      skeleton differently using a variety of methods (various bone densitometry devices and&#xD;
      ultrasound measurements of the bone) at a variety of bone sites (spine, hip, fingers, heel,&#xD;
      forearm and leg). These changes will be compared to changes in other markers of bone health&#xD;
      such as biochemical markers of bone turnover to help us determine the possible mechanism of&#xD;
      action for the different treatments. The study will last for 48 weeks which should be long&#xD;
      enough to detect signfiicant changes on bone strength as measured by DXA at the spine/hip. As&#xD;
      we are interested in how these changes occur there are more visits in the first three months&#xD;
      of the study than the last 9 months of the study. This is expected to help us detect the&#xD;
      difference between the onset of the effects of the three treatments more clearly.&#xD;
&#xD;
      Study vists will be: screening, baseline 1, baseline 2, 1 week, 2 weeks, 4 weeks, 12 weeks,&#xD;
      13 weeks (phone calls to participants at 24 and 36 weeks), 48 weeks and 49 weeks. The two&#xD;
      baseline visits will allow duplicate measurements of bone stregth/quality on different&#xD;
      occasions at the start of the study to minimise variability. Treatment will begin at baseline&#xD;
      2 (0 days) and last for 48 weeks. The visits at 13 weeks and 49 weeks are to perform bone&#xD;
      density/quality tests in duplicate to minimise variability as at baseline visit.&#xD;
&#xD;
      Bone mineral density of various bones (hip/spine/whole body and forearm) will be measured by&#xD;
      DXA on various devices, quantitative ultrasound will be performed at the heel and fingers,&#xD;
      and bone quality will be measured by pQCT at the forearm and tibia/3D analysis of the hip&#xD;
      scans at the baseline visits, at 12 and 13 weeks and at 48 and 49 week visits Surrogate&#xD;
      markers of bone health (biochemical markers of bone turnover) will be measured at baseline,&#xD;
      1, 2 4, 12, 13, 48 and 49 weeks. Exploratory methods included in the protocol include:&#xD;
      Assessing the number of bone breaking down cell numbers (osteoclasts) at baseline, 1 week and&#xD;
      48 weeks Assessing nail brittleness at baseline 12 and 48 weeks.&#xD;
&#xD;
      Subjects will be randomised using a stratification method to ensure all groups have an equal&#xD;
      range of bone strength at study entry. Randomisation will be performed by the hospital&#xD;
      pharmacy. The study is not blinded and subjects will know which treatment they are on.&#xD;
      Subjects will be asked not to discuss their assigned treatment with staff performing bone&#xD;
      measurements. There is no placebo group in this trial as all subjects will taking one of the&#xD;
      three treatments. We have chosen the active comparator design as many of the measurements&#xD;
      (especially the biochemical and cellular ones) do not change unless treatment is given; also,&#xD;
      these treatments are indicated and effective in this patients group.&#xD;
&#xD;
      To generate control data we will recruit a group of 200 healthy young women aged 35-40 years.&#xD;
      The control group will undertake all the measurements of bone strength/quality that the&#xD;
      treatment group will have as well as the biochemical maerkers of bone turnover. There will be&#xD;
      only 2 study visits for the control group,baseline and 48 weeks. This data will serve as&#xD;
      internal controls and as reference ranges for each of the devices used in the study. Ethical&#xD;
      considerations for this study include the use of ionising radiation, blood sampling at each&#xD;
      study visit and the number of study visits. This may be balanced by the close monitoring of&#xD;
      the subject whilst on the study and a thorough assessment of bone health for 49 weeks.&#xD;
      Research participants, patient groups or communities were not involved in the design of this&#xD;
      research study.&#xD;
&#xD;
      The hypothesis of the study is that bisphosphonates have varying magnitude of effect on&#xD;
      non-vertebral fractures and this is reflected in different changes in measures of bone&#xD;
      quality (QUS), bone density in the appendicular skeleton (DXA and pQCT) and novel biochemical&#xD;
      markers of bone resorption and osteoclast precursors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in heel broadband ultrasound attenuation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the percentage of MCSFR+ monocytes in the peripheral blood at baseline and after one week and 48 weeks of therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOS at finger and heel at 48 weeks.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lumbar spine and total hip BMD measured by DXA at 48 weeks</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in finger BMD measured by RA at 48 weeks</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heel BMD measured by DXL at 48 weeks</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distal tibia and ultradistal forearm cortical and trabecular volumetric BMD by pQCT at 48 weeks</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cathepsin K and MM enzyme and OPG and RANK-L protein at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in uNTX and uCTX. At 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disulfide bond content of nails at 48 weeks</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Post-menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibandronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risedronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate 70mg once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Young women control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>once monthly</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Bonviva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>Risedronate 35mg once weekly</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Actonel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate 70mg once weekly</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be female&#xD;
&#xD;
          -  at least 5 years post menopausal but &lt;85 years&#xD;
&#xD;
          -  BMD T-score (at the lumbar spine or total hip) of less than or equal to&#xD;
&#xD;
               -  2.5, or T-score less than or equal to -1 with a low trauma fracture.&#xD;
&#xD;
          -  be ambulatory&#xD;
&#xD;
          -  be able and willing to participate in the study and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have evidence of a clinically significant organic disease which could prevent the&#xD;
             patient from completing the study&#xD;
&#xD;
          -  have a BMI less than 18 or greater than 35&#xD;
&#xD;
          -  abuse alcohol or use illicit drugs or who consumed more than 4 servings of any&#xD;
             alcoholic beverage one day prior to the visit (i.e., subjects who might be binge&#xD;
             drinkers)&#xD;
&#xD;
          -  have any history of cancer within the past 5 years excluding skin cancer non melanomas&#xD;
&#xD;
          -  have a history of ongoing conditions or diseases known to cause abnormalities of&#xD;
             calcium metabolism or skeletal health (secondary osteoporosis)&#xD;
&#xD;
          -  Chronic renal disease (as defined by a creatinine clearance of â‰¤ 30ml/min)&#xD;
&#xD;
          -  Acute or chronic hepatic disease&#xD;
&#xD;
          -  Malabsorption syndromes&#xD;
&#xD;
          -  Hyperthyroidism as manifested by TSH outside the lower limit of the normal range&#xD;
&#xD;
          -  Hyperparathyroidism&#xD;
&#xD;
          -  Hypocalcemia or hypercalcemia&#xD;
&#xD;
          -  Osteomalacia&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  Patient who are currently on glucocorticoid therapy&#xD;
&#xD;
          -  have a serum calcium less than 2.2 mmol/l and a PTH above 75ng/l&#xD;
&#xD;
          -  have a history of any known condition that would interfere with the assessment of DXA&#xD;
             at either lumbar spine or femoral neck&#xD;
&#xD;
          -  have markedly abnormal clinical laboratory parameters that are assessed as clinically&#xD;
             significant by the investigator&#xD;
&#xD;
          -  use any of the following medications within 12 months of starting study drug&#xD;
&#xD;
               -  Bisphosphonates (at any dose)&#xD;
&#xD;
               -  Use of any fluoride with the exception use for oral hygiene&#xD;
&#xD;
               -  Strontium&#xD;
&#xD;
               -  Other bone agents (i.e., SERM, isoflavones, HRT etc)&#xD;
&#xD;
          -  have participated in another clinical trial involving active therapy 3 months prior to&#xD;
             randomisation&#xD;
&#xD;
          -  have a history of allergic reaction to bisphosphonates&#xD;
&#xD;
          -  patient taking calcium supplements within the last month prior to randomisation&#xD;
&#xD;
          -  We will exclude patients with secondary osteoporosis, those who have been on&#xD;
             anti-resorptive treatments in the past year, and women less than 5 years since&#xD;
             menopause, and those with bilateral fractures in the measurement regions (heel, hip&#xD;
             and forearm).&#xD;
&#xD;
          -  Have suffered a recent fracture within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene McCloskey, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosemary Hannon, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Rogers, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Paggiosi, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Unit of Bone Metabolism (Sheffield)</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <name_title>Professor Richard Eastell</name_title>
    <organization>University of Sheffield</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Post-menopausal osteoporosis</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>Alendronate</keyword>
  <keyword>Ibandronate</keyword>
  <keyword>Risedronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Risedronic Acid</mesh_term>
    <mesh_term>Ibandronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

